TipRanks (Mon, 6-May 9:21 AM ET)
Castle Biosciences’ Growth at Risk: How Loan Terms Could Hamper Business Agility
TipRanks (Sat, 4-May 2:02 AM ET)
TipRanks (Fri, 3-May 9:00 AM ET)
Business Wire (Fri, 3-May 7:00 AM ET)
Castle Biosciences beats Q1 estimates, raises FY guidance
Seeking Alpha News (Thu, 2-May 4:27 PM ET)
Castle Biosciences Unveils Informative Management Presentation Slides
TipRanks (Thu, 2-May 4:24 PM ET)
Castle Biosciences Reports First Quarter 2024 Results
Business Wire (Thu, 2-May 4:05 PM ET)
Castle Biosciences Q1 2024 Earnings Preview
Seeking Alpha News (Wed, 1-May 5:20 PM ET)
Business Wire (Tue, 30-Apr 4:30 PM ET)
Business Wire (Thu, 11-Apr 7:00 AM ET)
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Castle Biosciences trades on the NASDAQ stock market under the symbol CSTL.
As of May 6, 2024, CSTL stock price climbed to $24.50 with 225,047 million shares trading.
CSTL has a beta of 0.80, meaning it tends to be less sensitive to market movements. CSTL has a correlation of 0.01 to the broad based SPY ETF.
CSTL has a market cap of $675.88 million. This is considered a Small Cap stock.
Last quarter Castle Biosciences reported $73 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.24.
In the last 3 years, CSTL stock traded as high as $78.92 and as low as $9.26.
The top ETF exchange traded funds that CSTL belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.
CSTL stock has underperformed the market in the last year with a return of +6.9%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CSTL shares. However, CSTL has outperformed the market in the last 3 month and 2 week periods, returning +4.7% and +26.9%, while SPY returned +4.5% and +4.0%, respectively. This indicates CSTL has been having a stronger performance recently.
CSTL support price is $23.60 and resistance is $25.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CSTL stock will trade within this expected range on the day.